Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

PubWeight™: 0.75^‹?›

🔗 View Article (PMID 28950344)

Published in Eur Heart J Qual Care Clin Outcomes on August 16, 2017

Authors

Keith A A Fox¹, Gabriele Accetta², Karen S Pieper³, Jean-Pierre Bassand²^,4, A John Camm⁵^,6, David A Fitzmaurice⁷, Gloria Kayani², Ajay K Kakkar²^,8, GARFIELD-AF Investigators

Author Affiliations

1: Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK.
2: Thrombosis Research Institute, London, UK.
3: Duke Clinical Research Institute, Durham, North Carolina, USA.
4: University of Besançon Besançon, France.
5: Molecular and Clinical Sciences Research Institute, Cardiology Clinical Academic Group, St. George's University of London.
6: Imperial College, London, UK.
7: Warwick Medical School, University of Warwick, Coventry, UK.
8: University College London, London, UK.

Articles by these authors ⇆

Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open (2014) 0.92

Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J (2015) 0.90

Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation. Circ Cardiovasc Qual Outcomes (2015) 0.88

Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial. Am Heart J (2015) 0.87

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J (2016) 0.84

Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry. Int J Cardiol (2016) 0.82

Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart (2016) 0.80

International comparisons of acute myocardial infarction. Lancet (2014) 0.79

Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists. Br J Haematol (2016) 0.78

Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open (2017) 0.75

Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS One (2016) 0.75

Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. Heart (2016) 0.75

Prognostic value of dynamic electrocardiographic T wave changes in non-ST elevation acute coronary syndrome. Heart (2016) 0.75

Erratum. Eur Heart J Qual Care Clin Outcomes (2017) 0.75

Evolving quality standards for large-scale registries: the GARFIELD-AF experience. Eur Heart J Qual Care Clin Outcomes (2017) 0.75

Electrocardiographic Findings in Patients With Acute Coronary Syndrome Presenting With Out-of-Hospital Cardiac Arrest. Am J Cardiol (2017) 0.75

GRACE risk score: Sex-based validity of in-hospital mortality prediction in Canadian patients with acute coronary syndrome. Int J Cardiol (2017) 0.75

Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-ST-Segment Elevation Acute Coronary Syndrome. Clin Chem (2017) 0.75